Cancer Science

OCT 23, 2026 · JOURNAL ARTICLE

Dioscin Promotes Ferroptosis in Cervical Cancer Cells via the TIGAR ‐ ROS Axis

Cancer Science

ABSTRACT Cervical cancer seriously threatens women's life and health, highlighting the urgent need for targeted therapies. TP53‐induced glycolysis regulatory phosphatase (TIGAR), u

OCT 18, 2026 · JOURNAL ARTICLE

CDK4 /6 Inhibitors and Curcumin Synergistically Suppress HER2 − Breast Cancer via Lethal ROS and Inhibition of Metastasis

Cancer Science

ABSTRACT CDK4/6 inhibitors represent a key therapy for HR+/HER2− breast cancer, yet resistance and limited efficacy in triple‐negative breast cancer (TNBC) remain significant chall

SEP 22, 2026 · JOURNAL ARTICLE

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science

ABSTRACT In advanced non‐squamous non‐small cell lung cancer (non‐sq NSCLC), companion diagnostic testing (CDx) identifies actionable driver alterations and guides initial targeted

SEP 20, 2026 · JOURNAL ARTICLE

Cord Blood‐Derived Fibroblast Activation Protein‐Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo

Cancer Science

ABSTRACT Cancer‐associated fibroblasts (CAFs) have been recognized as key contributors to tumor progression. Chimeric antigen receptor (CAR) T‐cell therapy targeting fibroblast act

SEP 18, 2026 · JOURNAL ARTICLE

Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer

Cancer Science

ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and application prospects of radiotherapy in neoadjuvant therapy for stage III n

SEP 5, 2026 · JOURNAL ARTICLE

Efficacy and Safety of DVDMS ‐Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial

Cancer Science

Phase II trial with modest sample size showing acceptable safety profile and 40% response rate for dysphagia in advanced esophageal cancer, but requires larger confirmatory studies before clinical adoption.

AUG 19, 2026 · JOURNAL ARTICLE

Genetic Engineering of Tumor‐Infiltrating Lymphocytes ( TIL ) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

Cancer Science

Early-stage mechanistic work demonstrating proof-of-concept for a gene-editing platform in preclinical and PDX models, without human clinical efficacy data or direct comparison to standard TIL therapy.

AUG 13, 2026 · JOURNAL ARTICLE

TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776 ‐Altered Subtype of HER2 ‐Mutant NSCLC

Cancer Science

A validated two-stage clinicogenomic discovery study identifying a recurrent co-mutation association in a molecularly defined NSCLC subtype, but limited by small sample sizes in functional or treatment-outcome validation and lack of prospective clinical utility data.